Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
02:18pm, Tuesday, 06'th Jan 2026
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Mo
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
11:20am, Tuesday, 06'th Jan 2026
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
11:59am, Monday, 05'th Jan 2026
Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagn
Incyte's blood cancer therapy meets main goal in late-stage trial
07:40am, Monday, 05'th Jan 2026
Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL.
CWA Asset Management Group LLC Acquires New Holdings in Incyte Corporation $INCY
04:26am, Monday, 05'th Jan 2026
CWA Asset Management Group LLC bought a new position in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bou
Generali Asset Management SPA SGR Reduces Holdings in Incyte Corporation $INCY
05:36am, Sunday, 04'th Jan 2026
Generali Asset Management SPA SGR reduced its stake in Incyte Corporation (NASDAQ: INCY) by 20.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commiss
Perigon Wealth Management LLC Purchases Shares of 5,365 Incyte Corporation $INCY
05:18am, Saturday, 03'rd Jan 2026
Perigon Wealth Management LLC purchased a new stake in shares of Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent filing with the Securities and Exchange Co
Continuum Advisory LLC Buys 5,185 Shares of Incyte Corporation $INCY
05:01am, Tuesday, 30'th Dec 2025
Continuum Advisory LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 7.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co.
04:50am, Sunday, 28'th Dec 2025
Burney Co. bought a new stake in Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institution
Incyte (NASDAQ:INCY) Insider Thomas Tray Sells 600 Shares of Stock
06:05am, Tuesday, 23'rd Dec 2025
Incyte Corporation (NASDAQ: INCY - Get Free Report) insider Thomas Tray sold 600 shares of Incyte stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average pric
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
10:06am, Monday, 22'nd Dec 2025
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
02:42am, Monday, 22'nd Dec 2025
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
10:31am, Thursday, 18'th Dec 2025
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
